SK Project, Medical Innovation Center, Kyoto University Graduate School of Medicine, 53 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029; Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029; Nash Family Department of Neuroscience, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029; Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029; Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029.
SK Project, Medical Innovation Center, Kyoto University Graduate School of Medicine, 53 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan.
Neuron. 2024 Apr 17;112(8):1265-1285.e10. doi: 10.1016/j.neuron.2024.01.023. Epub 2024 Feb 19.
Despite the rapid and sustained antidepressant effects of ketamine and its metabolites, their underlying cellular and molecular mechanisms are not fully understood. Here, we demonstrate that the sustained antidepressant-like behavioral effects of (2S,6S)-hydroxynorketamine (HNK) in repeatedly stressed animal models involve neurobiological changes in the anterior paraventricular nucleus of the thalamus (aPVT). Mechanistically, (2S,6S)-HNK induces mRNA expression of extrasynaptic GABA receptors and subsequently enhances GABA-receptor-mediated tonic currents, leading to the nuclear export of histone demethylase KDM6 and its replacement by histone methyltransferase EZH2. This process increases H3K27me3 levels, which in turn suppresses the transcription of genes associated with G-protein-coupled receptor signaling. Thus, our findings shed light on the comprehensive cellular and molecular mechanisms in aPVT underlying the sustained antidepressant behavioral effects of ketamine metabolites. This study may support the development of potentially effective next-generation pharmacotherapies to promote sustained remission of stress-related psychiatric disorders.
尽管氯胺酮及其代谢物具有快速和持续的抗抑郁作用,但它们的潜在细胞和分子机制尚不完全清楚。在这里,我们证明(2S,6S)-羟基去甲氯胺酮(HNK)在反复应激动物模型中的持续抗抑郁样行为效应涉及到丘脑前室旁核(aPVT)的神经生物学变化。从机制上讲,(2S,6S)-HNK 诱导了突触外 GABA 受体的 mRNA 表达,随后增强了 GABA 受体介导的紧张电流,导致组蛋白去甲基化酶 KDM6 的核输出,并被组蛋白甲基转移酶 EZH2 取代。这一过程增加了 H3K27me3 的水平,从而抑制了与 G 蛋白偶联受体信号相关的基因的转录。因此,我们的研究结果阐明了 aPVT 中氯胺酮代谢物持续抗抑郁行为效应的全面细胞和分子机制。这项研究可能支持开发潜在有效的下一代药物治疗方法,以促进与应激相关的精神障碍的持续缓解。